PotentialBPC-157 en TB-500synergy in WoundRepairUit onderzoek blijkt dat BPC-157 en TB-500, die beide helpen bij het stimuleren van wondgenezing Via verschillende biochemische routes, kan synergetische effecten hebben wanneer ze worden gecombineerd.CelmigratieSuccesvolle wondgenezing is afhankelijk van fibroblasten, die de productie van extracellulaire matrix reguleren, evenals cellen van het immuunsysteem. Voor deze cellen om hun werk te doen, hebben ze naar de locatie van letsel gaan. Deze beweging, migratie genoemd, is sterk afhankelijk van het eiwitactine. Zowel BPC-157 als TB-500 zijn belangrijk in Actin Regulation BPC-157 werkt op het niveau van het gen om de actineproductie te verhogen [1]. TB-500, een actinbindend eiwit, helpt actine te sekwestreren in gebieden waar het het meest nuttig is voor bouwfilamenten van actine om celbeweging mogelijk te maken [2]. Samen werken BPC-157 en TB-500 werken om de hoeveelheid en functie van actine te vergroten en dus de snelheid te verhogen waar fibroblasten en cellen van het immuunsysteem naar letsel migreren.Het grote beeld is GrowthHormoneZowel TB-500 als BPC-157 interageren met groeihormoon in het genezingsproces. BPC-157 neemt de expressie van groeihormoonreceptoren op fibroblasten in, waardoor de thelongevity van deze cellen wordt gestimuleerd en dus hun vermogen om de regeneratie van zachte weefsel te bevorderen [3]. Met TB-500 aan boord zullen de extra groeihormoonreceptoren niet verloren gaan omdat de fibroblasten voldoende winkels van actine zullen hebben om gebruik te maken van hun langwerpige levensduur.Over de auteurDe bovenstaande literatuur werd onderzocht, bewerkt en georganiseerd door Dr. E. Logan, M.D. Dr. Elogan behaalde een doctoraat aan de Case Western Reserve University School of Medicine en A B.S. in moleculaire biologie.Wetenschappelijke journa auteurAllan L. Goldstein, MD, Allan L. Goldstein is professor and Catharine B. & WiliamMcCormick Chair of the department of Biochemistry and Molecular Biology at TheGeorge Washington University School of Medicine and Health Sciences, where he hasserved since 1978. Thymosins were discovered in the mid 1960’s, when Allan Goldsteinfrom the Laboratory of Abraham White at the Albert Einstein College of Medicine in NewYork studied the role of the thymus in development of the vertebrate immune system. Heis a world-renowned authority on the thymus gland and the workings of the immunesystem, and co-discoverer of the thymosins. Dr. Goldstein is the author of over 400 scientific articles in professional journals, the inventor on more than 15 U.S. Patents, andthe editor of several books in the fields of biochemistry, biomedicine, immunology andneuro-science. He is on the editorial boards of numerous scientific and medical journalsand has been a consultant to many re-search organizations in industry and government;,co-founder of The institute for Advanced Studies in Aging and Geriatric Medicine, a non-profit research and educational institute; a member of the Board of Trustees of the AlbertSabin Vaccine Institute, and serves as the Chairman of the Board of Regene Rx Biopharmaceuticals. Dr. Goldstein received his B.S. from Wagner College in 1959 and hisM.S. and Ph.D. from Rutgers University in 1964. He served as a faculty member of theAlbert Einstein College of Medicine from 1964 to 1972, and moved to the University ofTexas Medical Branch in Galveston in 1972 as professor and director of the division of Biochemistry.
Allan L. Goldstein, MD is being referenced as one of the leading scientists involved in theresearch and development of TB-500 and other Thymosins. In no way is thisdoctor/scientist endorsing or advocating the purchase, sale, or use of this product for anyreason. There is no affiliation or relationship, implied or otherwise, between PeptideSciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize.and credit the exhaustive research and development efforts conducted by the scientistsstudying this peptide. Dr. Goldstein is listed in [5]under the referenced citations.Bronnen1.C.-H. Chang, W.-C. Tsai, M.-S. Lin, Y-H. Hsu, and J.-H. S. Pang, “The promotingeffect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth,cell survival, and cell migration,”J.Appl. Physiol., vol. 110, no.3, pp.774-780, Oct[Physiology.org]
2.J. Kim and Y. Jung, “Potential Role of Thymosin Beta 4 in Liver Fibrosis,” Int. J.Mol. Sci., vol.16,no.5,pp.10624-10635,May 2015.[NCBI]
3.C.-H. Chang, W.-C. Tsai, Y.-H. Hsu, and J.-H.S.Pang,“Pentadecapeptide BPC157 enhances the growth hormone receptor expression in tendon fibroblasts,” Mol.Basel Switz.,vol.19,no.11,pp.19066-19077, NOV. 2014.[NCBI]
4.Song, Ran & Choi, Hyun & Yang, Hyung-In & Yoo, Myung & Park, Yong-Beom &Kim, Kyoung.(2012).Association between serum thymosin B4 levels of rheumatoidarthritis patients and disease activity and response to therapy. Clinicalrheumatology.31.1253-8.10.1007/s10067-012-2011-7.[Research Gate]
5.Philp, D., et al. “Thymosin β4 Promotes Angiogenesis, Wound Healing, and HairFollicle Development.”Mechanisms ofAgeing and Development, vol. 125, no. 2Feb.2004,pp.113-115,10.1016/i.mad.2003.11.005.[PubMed]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. in-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
